Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 397

1.

Founder Effects of Spinocerebellar Ataxias in the American Continents and the Caribbean.

Rodríguez-Labrada R, Martins AC, Magaña JJ, Vazquez-Mojena Y, Medrano-Montero J, Fernandez-Ruíz J, Cisneros B, Teive H, McFarland KN, Saraiva-Pereira ML, Cerecedo-Zapata CM, Gomez CM, Ashizawa T, Velázquez-Pérez L, Jardim LB; PanAmerican Hereditary Ataxia Network.

Cerebellum. 2020 Feb 21. doi: 10.1007/s12311-020-01109-7. [Epub ahead of print] Review.

PMID:
32086717
2.

Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.

Ashizawa T, Iizuka A, Tanaka E, Kondou R, Miyata H, Maeda C, Sugino T, Yamaguchi K, Ando T, Ishikawa Y, Ito M, Akiyama Y.

Biomed Res. 2019;40(6):243-250. doi: 10.2220/biomedres.40.243.

3.

Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1.

Johnson NE, Aldana EZ, Angeard N, Ashizawa T, Berggren KN, Marini-Bettolo C, Duong T, Ekström AB, Sansone V, Tian C, Hellerstein L, Campbell C.

Neurol Clin Pract. 2019 Oct;9(5):443-454. doi: 10.1212/CPJ.0000000000000646. Review.

4.

Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status.

Ashizawa T, Iizuka A, Maeda C, Tanaka E, Kondou R, Miyata H, Sugino T, Kawata T, Deguchi S, Mitsuya K, Hayashi N, Asai A, Ito M, Yamaguchi K, Akiyama Y.

Immunol Lett. 2019 Dec;216:43-50. doi: 10.1016/j.imlet.2019.10.003. Epub 2019 Oct 3.

5.

Spinocerebellar Ataxia Type 10.

Matsuura T, Ashizawa T.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020.
2002 Apr 23 [updated 2019 Sep 19].

6.

Clinical and Genetic Evaluation of Spinocerebellar Ataxia Type 10 in 16 Brazilian Families.

Domingues BMD, Nascimento FA, Meira AT, Moro A, Raskin S, Ashizawa T, Teive HAG.

Cerebellum. 2019 Oct;18(5):849-854. doi: 10.1007/s12311-019-01064-y.

PMID:
31377949
7.

Spinocerebellar ataxias in Southern Brazil: Genotypic and phenotypic evaluation of 213 families.

Nascimento FA, Rodrigues VOR, Pelloso FC, Camargo CHF, Moro A, Raskin S, Ashizawa T, Teive HAG.

Clin Neurol Neurosurg. 2019 Sep;184:105427. doi: 10.1016/j.clineuro.2019.105427. Epub 2019 Jul 10.

PMID:
31323545
8.

Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription.

Gao R, Chakraborty A, Geater C, Pradhan S, Gordon KL, Snowden J, Yuan S, Dickey AS, Choudhary S, Ashizawa T, Ellerby LM, La Spada AR, Thompson LM, Hazra TK, Sarkar PS.

Elife. 2019 Apr 17;8. pii: e42988. doi: 10.7554/eLife.42988.

9.

Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy.

Nonomura C, Otsuka M, Kondou R, Iizuka A, Miyata H, Ashizawa T, Sakura N, Yoshikawa S, Kiyohara Y, Ohshima K, Urakami K, Nagashima T, Ohnami S, Kusuhara M, Mitsuya K, Hayashi N, Nakasu Y, Mochizuki T, Yamaguchi K, Akiyama Y.

Immunol Lett. 2019 Apr;208:52-59. doi: 10.1016/j.imlet.2019.02.004. Epub 2019 Mar 14.

10.

Tremor in the Degenerative Cerebellum: Towards the Understanding of Brain Circuitry for Tremor.

Lai RY, Tomishon D, Figueroa KP, Pulst SM, Perlman S, Wilmot G, Gomez CM, Schmahmann JD, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Cerebellum. 2019 Jun;18(3):519-526. doi: 10.1007/s12311-019-01016-6.

PMID:
30830673
11.

99mTc-TRODAT-1 SPECT Showing Dopaminergic Deficiency in a Patient with Spinocerebellar Ataxia Type 10 and Parkinsonism.

Fabiani G, Martins R, Ashizawa T, Germiniani FMB, Teive HAG.

Mov Disord Clin Pract. 2018 Nov 16;6(1):85-87. doi: 10.1002/mdc3.12700. eCollection 2019 Jan. No abstract available.

12.

A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.

Iizuka A, Nonomura C, Ashizawa T, Kondou R, Ohshima K, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Maruyama K, Yamaguchi K, Akiyama Y.

Clin Cancer Res. 2019 May 1;25(9):2925-2934. doi: 10.1158/1078-0432.CCR-17-3123. Epub 2019 Feb 8.

PMID:
30737243
13.

Consensus-based care recommendations for adults with myotonic dystrophy type 1.

Ashizawa T, Gagnon C, Groh WJ, Gutmann L, Johnson NE, Meola G, Moxley R 3rd, Pandya S, Rogers MT, Simpson E, Angeard N, Bassez G, Berggren KN, Bhakta D, Bozzali M, Broderick A, Byrne JLB, Campbell C, Cup E, Day JW, De Mattia E, Duboc D, Duong T, Eichinger K, Ekstrom AB, van Engelen B, Esparis B, Eymard B, Ferschl M, Gadalla SM, Gallais B, Goodglick T, Heatwole C, Hilbert J, Holland V, Kierkegaard M, Koopman WJ, Lane K, Maas D, Mankodi A, Mathews KD, Monckton DG, Moser D, Nazarian S, Nguyen L, Nopoulos P, Petty R, Phetteplace J, Puymirat J, Raman S, Richer L, Roma E, Sampson J, Sansone V, Schoser B, Sterling L, Statland J, Subramony SH, Tian C, Trujillo C, Tomaselli G, Turner C, Venance S, Verma A, White M, Winblad S.

Neurol Clin Pract. 2018 Dec;8(6):507-520. doi: 10.1212/CPJ.0000000000000531. Review.

14.

Polymorphisms in DNA methylation-related genes are linked to the phenotype of Machado-Joseph disease.

Ding D, Wang C, Chen Z, Peng H, Li K, Zhou X, Peng Y, Wang P, Hou X, Li T, Qiu R, Xia K, Sequeiros J, Ashizawa T, Tang B, Jiang H.

Neurobiol Aging. 2019 Mar;75:225.e1-225.e8. doi: 10.1016/j.neurobiolaging.2018.11.002. Epub 2018 Nov 16.

PMID:
30554804
15.

Human iPSC Models to Study Orphan Diseases: Muscular Dystrophies.

Xia G, Terada N, Ashizawa T.

Curr Stem Cell Rep. 2018;4(4):299-309. doi: 10.1007/s40778-018-0145-5. Epub 2018 Oct 4. Review.

16.

Author Correction: Spinocerebellar ataxias: prospects and challenges for therapy development.

Ashizawa T, Öz G, Paulson HL.

Nat Rev Neurol. 2018 Dec;14(12):749. doi: 10.1038/s41582-018-0102-z.

PMID:
30410042
17.

Classification of tumor microenvironment immune types based on immune response-associated gene expression.

Kondou R, Iizuka A, Nonomura C, Miyata H, Ashizawa T, Nagashima T, Ohshima K, Urakami K, Kusuhara M, Yamaguchi K, Akiyama Y.

Int J Oncol. 2019 Jan;54(1):219-228. doi: 10.3892/ijo.2018.4617. Epub 2018 Nov 2.

PMID:
30387832
18.

Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9.

Wang Y, Hao L, Wang H, Santostefano K, Thapa A, Cleary J, Li H, Guo X, Terada N, Ashizawa T, Xia G.

Mol Ther. 2018 Nov 7;26(11):2617-2630. doi: 10.1016/j.ymthe.2018.09.003. Epub 2018 Sep 11.

19.

SCA8 RAN polySer protein preferentially accumulates in white matter regions and is regulated by eIF3F.

Ayhan F, Perez BA, Shorrock HK, Zu T, Banez-Coronel M, Reid T, Furuya H, Clark HB, Troncoso JC, Ross CA, Subramony SH, Ashizawa T, Wang ET, Yachnis AT, Ranum LP.

EMBO J. 2018 Oct 1;37(19). pii: e99023. doi: 10.15252/embj.201899023. Epub 2018 Sep 11.

20.

Spinocerebellar ataxias: prospects and challenges for therapy development.

Ashizawa T, Öz G, Paulson HL.

Nat Rev Neurol. 2018 Oct;14(10):590-605. doi: 10.1038/s41582-018-0051-6. Review. Erratum in: Nat Rev Neurol. 2018 Dec;14(12):749.

21.

Longitudinal analysis of contrast acuity in Friedreich ataxia.

Hamedani AG, Hauser LA, Perlman S, Mathews K, Wilmot GR, Zesiewicz T, Subramony SH, Ashizawa T, Delatycki MB, Brocht A, Lynch DR.

Neurol Genet. 2018 Jul 23;4(4):e250. doi: 10.1212/NXG.0000000000000250. eCollection 2018 Aug.

22.

Intravenously Administered Novel Liposomes, DCL64, Deliver Oligonucleotides to Cerebellar Purkinje Cells.

Ashizawa AT, Holt J, Faust K, Liu W, Tiwari A, Zhang N, Ashizawa T.

Cerebellum. 2019 Feb;18(1):99-108. doi: 10.1007/s12311-018-0961-2.

23.

Olfactory Function in SCA10.

Moscovich M, Munhoz RP, Moro A, Raskin S, McFarland K, Ashizawa T, Teive HAG, Silveira-Moriyama L.

Cerebellum. 2019 Feb;18(1):85-90. doi: 10.1007/s12311-018-0954-1.

24.

Body composition in Spinocerebellar ataxia type 3 and 10 patients: Comparative study with control group.

Leite CMBA, Schieferdecker MEM, Frehner C, Munhoz RP, Ashizawa T, Teive HAG.

Nutr Neurosci. 2020 Jan;23(1):49-54. doi: 10.1080/1028415X.2018.1469282. Epub 2018 May 7.

PMID:
29734917
25.

Sleep disorders in spinocerebellar ataxia type 10.

London E, Camargo CHF, Zanatta A, Crippa AC, Raskin S, Munhoz RP, Ashizawa T, Teive HAG.

J Sleep Res. 2018 Oct;27(5):e12688. doi: 10.1111/jsr.12688. Epub 2018 Apr 6.

26.

Intron retention induced by microsatellite expansions as a disease biomarker.

Sznajder ŁJ, Thomas JD, Carrell EM, Reid T, McFarland KN, Cleary JD, Oliveira R, Nutter CA, Bhatt K, Sobczak K, Ashizawa T, Thornton CA, Ranum LPW, Swanson MS.

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):4234-4239. doi: 10.1073/pnas.1716617115. Epub 2018 Apr 2.

27.

Spinocerebellar ataxias type 3 and 10: Onset and progression of ataxia during pregnancy and puerperium.

Silva GV, Bonilha P, Moro A, Munhoz R, Raskin S, Ashizawa T, Nascimento FA, Teive HAG.

Parkinsonism Relat Disord. 2018 Jul;52:119-120. doi: 10.1016/j.parkreldis.2018.03.025. Epub 2018 Mar 27. No abstract available.

PMID:
29609848
28.

A crystal ball for survival for spinocerebellar ataxias?

Ashizawa T.

Lancet Neurol. 2018 Apr;17(4):292-294. doi: 10.1016/S1474-4422(18)30088-7. Epub 2018 Mar 13. No abstract available.

PMID:
29553373
29.

Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Zesiewicz TA, Wilmot G, Kuo SH, Perlman S, Greenstein PE, Ying SH, Ashizawa T, Subramony SH, Schmahmann JD, Figueroa KP, Mizusawa H, Schöls L, Shaw JD, Dubinsky RM, Armstrong MJ, Gronseth GS, Sullivan KL.

Neurology. 2018 Mar 6;90(10):464-471. doi: 10.1212/WNL.0000000000005055. Epub 2018 Feb 9.

30.

Immune response-associated gene profiling in Japanese melanoma patients using multi-omics analysis.

Akiyama Y, Kiyohara Y, Yoshikawa S, Otsuka M, Kondou R, Nonomura C, Miyata H, Iizuka A, Ashizawa T, Ohshima K, Urakami K, Nagashima T, Kusuhara M, Sugino T, Yamaguchi K.

Oncol Rep. 2018 Mar;39(3):1125-1131. doi: 10.3892/or.2017.6173. Epub 2017 Dec 21.

PMID:
29286146
31.

C9orf72 repeat expansions as genetic modifiers for depression in spinocerebellar ataxias.

Figueroa KP, Gan SR, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Pulst SM, Kuo SH.

Mov Disord. 2018 Mar;33(3):497-498. doi: 10.1002/mds.27258. Epub 2017 Nov 29. No abstract available.

32.

Correction to: SPG7 and Impaired Emotional Communication.

Zhang L, McFarland KN, Subramony SH, Heilman KM, Ashizawa T.

Cerebellum. 2017 Dec;16(5-6):991. doi: 10.1007/s12311-017-0901-6.

PMID:
29181771
33.

Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.

Mikami S, Kawasaki M, Ikeda S, Negoro N, Nakamura S, Nomura I, Ashizawa T, Kokubo H, Hoffman ID, Zou H, Oki H, Uchiyama N, Hiura Y, Miyamoto M, Itou Y, Nakashima M, Iwashita H, Taniguchi T.

Chem Pharm Bull (Tokyo). 2017;65(11):1058-1077. doi: 10.1248/cpb.c17-00564.

34.

Dystonia and ataxia progression in spinocerebellar ataxias.

Kuo PH, Gan SR, Wang J, Lo RY, Figueroa KP, Tomishon D, Pulst SM, Perlman S, Wilmot G, Gomez CM, Schmahmann JD, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind MD, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Parkinsonism Relat Disord. 2017 Dec;45:75-80. doi: 10.1016/j.parkreldis.2017.10.007. Epub 2017 Oct 23.

35.

Postural Tremor and Ataxia Progression in Spinocerebellar Ataxias.

Gan SR, Wang J, Figueroa KP, Pulst SM, Tomishon D, Lee D, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind MD, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Tremor Other Hyperkinet Mov (N Y). 2017 Oct 9;7:492. doi: 10.7916/D8GM8KRH. eCollection 2017.

36.

RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2.

Zu T, Cleary JD, Liu Y, Bañez-Coronel M, Bubenik JL, Ayhan F, Ashizawa T, Xia G, Clark HB, Yachnis AT, Swanson MS, Ranum LPW.

Neuron. 2017 Sep 13;95(6):1292-1305.e5. doi: 10.1016/j.neuron.2017.08.039.

37.

Parkinson's disease associated with pure ATXN10 repeat expansion.

Schüle B, McFarland KN, Lee K, Tsai YC, Nguyen KD, Sun C, Liu M, Byrne C, Gopi R, Huang N, Langston JW, Clark T, Gil FJJ, Ashizawa T.

NPJ Parkinsons Dis. 2017 Sep 5;3:27. doi: 10.1038/s41531-017-0029-x. eCollection 2017.

38.

Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.

Mikami S, Nakamura S, Ashizawa T, Nomura I, Kawasaki M, Sasaki S, Oki H, Kokubo H, Hoffman ID, Zou H, Uchiyama N, Nakashima K, Kamiguchi N, Imada H, Suzuki N, Iwashita H, Taniguchi T.

J Med Chem. 2017 Sep 28;60(18):7677-7702. doi: 10.1021/acs.jmedchem.7b00807. Epub 2017 Sep 5.

PMID:
28796496
39.

The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.

Akiyama Y, Nonomura C, Ashizawa T, Iizuka A, Kondou R, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Asai A, Ito M, Kiyohara Y, Yamaguchi K.

Immunol Lett. 2017 Oct;190:20-25. doi: 10.1016/j.imlet.2017.07.005. Epub 2017 Jul 15.

PMID:
28716484
40.

Spinocerebellar Ataxia Type 1.

Opal P, Ashizawa T.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020.
1998 Oct 1 [updated 2017 Jun 22].

41.

Nonmotor Symptoms in Patients with Spinocerebellar Ataxia Type 10.

Moro A, Munhoz RP, Moscovich M, Arruda WO, Raskin S, Silveira-Moriyama L, Ashizawa T, Teive HAG.

Cerebellum. 2017 Dec;16(5-6):938-944. doi: 10.1007/s12311-017-0869-2.

42.

Inheritance patterns of ATCCT repeat interruptions in spinocerebellar ataxia type 10 (SCA10) expansions.

Landrian I, McFarland KN, Liu J, Mulligan CJ, Rasmussen A, Ashizawa T.

PLoS One. 2017 Apr 19;12(4):e0175958. doi: 10.1371/journal.pone.0175958. eCollection 2017.

43.

A Comparative Optical Coherence Tomography Study of Spinocerebellar Ataxia Types 3 and 10.

Spina Tensini F, Sato MT, Shiokawa N, Ashizawa T, Teive HAG.

Cerebellum. 2017 Aug;16(4):797-801. doi: 10.1007/s12311-017-0856-7.

44.

Ubiquitin-related network underlain by (CAG)n loci modulate age at onset in Machado-Joseph disease.

Chen Z, Wang C, Zheng C, Long Z, Cao L, Li X, Shang H, Yin X, Zhang B, Liu J, Ding D, Peng Y, Peng H, Ye W, Qiu R, Pan Q, Xia K, Chen S, Sequeiros J, Ashizawa T, Tang B, Jiang H; Chinese Clinical Research Cooperative Group for Spinocerebellar Ataxias (CCRCG-SCA).

Brain. 2017 Apr 1;140(4):e25. doi: 10.1093/brain/awx028. No abstract available.

PMID:
28334945
45.

RNA toxicity and foci formation in microsatellite expansion diseases.

Zhang N, Ashizawa T.

Curr Opin Genet Dev. 2017 Jun;44:17-29. doi: 10.1016/j.gde.2017.01.005. Epub 2017 Feb 14. Review.

46.

Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line.

Miyata H, Ashizawa T, Iizuka A, Kondou R, Nonomura C, Sugino T, Urakami K, Asai A, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K, Akiyama Y.

Cancer Genomics Proteomics. 2017 Jan 2;14(1):83-91.

47.

The Initial Symptom and Motor Progression in Spinocerebellar Ataxias.

Luo L, Wang J, Lo RY, Figueroa KP, Pulst SM, Kuo PH, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Cerebellum. 2017 Jun;16(3):615-622. doi: 10.1007/s12311-016-0836-3.

48.

Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.

Iizuka A, Kondou R, Nonomura C, Ashizawa T, Ohshima K, Kusuhara M, Isaka M, Ohde Y, Yamaguchi K, Akiyama Y.

Oncol Rep. 2016 Nov;36(5):2625-2632. doi: 10.3892/or.2016.5084. Epub 2016 Sep 12.

PMID:
27632942
49.

Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells.

Akiyama Y, Nonomura C, Kondou R, Miyata H, Ashizawa T, Maeda C, Mitsuya K, Hayashi N, Nakasu Y, Yamaguchi K.

Int J Oncol. 2016 Sep;49(3):1099-107. doi: 10.3892/ijo.2016.3586. Epub 2016 Jun 29.

PMID:
27573705
50.

SPG7 and Impaired Emotional Communication.

Zhang L, McFarland KN, Subramony SH, Heilman KM, Ashizawa T.

Cerebellum. 2017 Apr;16(2):595-598. doi: 10.1007/s12311-016-0818-5. Erratum in: Cerebellum. 2017 Nov 27;:.

Supplemental Content

Loading ...
Support Center